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The first human liver transplantation was 
performed by Thomas Starzl in 1963. Orthotopic 
liver transplantation (OLT) has evolved dramati-
cally over the past 50 years and it is now 
established as a definitive treatment of most 
types of liver failure [1]. However, whole organ 
transplantation is mostly limited by the 
unavailability of a sufficient number of suitable 
donor organs. Therefore, other approaches such 
as hepatocyte transplantation and tissue 
engineering represent an area of intense 
investigation. 
rapy was first attempted by James Wilson in a patient 
ipidaemia [8]. A segment of the patient’s liver was 
cytes were then infected ex vivo with the retrovirus 
e encouraging early biochemical correction, however, 
d induced pluripotent stem cells (iPSc) in combination 
ogies were used by Ludovic Vallier to correct mutations 
 patients with alpha1-anti-trypsin deficiency using zinc 
nsposon. The corrected iPSc were then differentiated 
tested in vivo in a mouse model thus providing the first 
idualised liver cell therapy using iPSc [9].
In 1992, Starzl and Colleagues transplanted 
baboon livers into patients with HIV infection 
and advanced hepatitis B, who survived 27 
and 70 days, respectively. However, massive 
immunosuppression was necessary thus 
leading to fatal infections in both patients [5]. 
Indeed the immunological barrier, mediated 
by xenoreactive natural antibodies (XNA) 
against a surface antigen (α-Gal) on porcine 
endothelial cells [6], represents the major 
limitation for xenotrasplantation. 
Bioartificial liver (BAL) support systems aim to 
temporarily replace the metabolic and excretory 
functions of the liver until the patients’ own liver 
has recovered or a donor liver becomes 
available for transplant. The main components 
of BAL are extracorporeal bioreactors in which 
liver cells are cultured in a network of hollow 
fibres for blood plasma perfusion. Several 
clinical trials have been performed using this 
technology in patients with acute or 
acute-on-chronic liver failure.  A recent 
meta-analysis has shown an improvement in 
survival in patients with acute liver failure while 
there was no evidence that this system improved 
survival in acute-on-chronic liver failure [7].
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hepatocytes were used to generate 
transplantable recellularized liver grafts. 
Long-term transplantation of engineered 
rat livers using decellularised matrices 
have demonstrated to be efficient in 90% 
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